NHS Could Save £350 Million Yearly From Generic Lipitor

The admittance of generic forms of Pfizer’s cholesterol lowering drug, Lipitor (atorvastatin), onto the UK market could in time save the NHS £350 million annually. According to the Generic Manufacturers’ Association, the loss of Lipitor’s patent protection in the UK and the accessibility of lower cost generic forms “will mean prices dropping significantly in the

Continue Reading

UK Researchers Halt Brain Cell Death in Mice

UK researchers have exposed the basis of what could become a new method to treat degenerative brain illnesses such as Alzheimer’s and Parkinson’s. Scientists from the University of Leicester have, by tackling a new pathway, managed to stop brain cell death in mice with prion disease, a progressive disorder that affects the nervous system in

Continue Reading

MHRA Reveals New Strategy to Crack Down on Fake Drugs

The MHRA (Medicines and Healthcare products Regulatory Agency), a government agency responsible for ensuring that medicines and medical devices work and are acceptably safe, has revealed their new anti-counterfeiting policy to increase the clamp down on fake drugs arriving in the UK supply chain. Developing on the achievements of the initial action plan, the new

Continue Reading

Strong Vyvanse Sales Boost Shire’s First Quarter

Shire posted another strong set of results yesterday, with a 20 percent rise in first-quarter earnings, just beating market expectations, and their attention-deficit hyperactivity disorder (ADHD) treatments and rare disease drugs once again performing well. Shire, whose development has outstripped the industry thanks to its acquisitive strategy, reported earnings per ADS (American Depositary Share) of

Continue Reading

GlaxoSmithKline Announce Q1 Results

Pharmaceutical drug maker, GlaxoSmithKline (GSK), today announced that their revenue increased just 1% in the first quarter, reflecting burdens on the organisation from government price cuts in Europe and some emerging markets, and hard year-by-year comparisons. GSK’s results were boosted by the sale of U.S. rights to a bladder drug, which added approximately £170 million

Continue Reading